Cytos cuts jobs after hypertension vaccine fails Phase II trial
This article was originally published in Scrip
Executive Summary
Cytos Biotechnology will reduce its workforce by 40% after its antihypertensive vaccine candidate, CYT006-AngQb, failed a Phase IIa trial, causing its shares to tumble by 31% to CHF15.15 on the Swiss Exchange on March 17th.